Research Study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Group-sequential, Adaptive, Phase 3 Study With Open-label Extension Period to Assess the Efficacy and Safety of Selexipag as an add-on to Standard of Care Therapy in Subjects With Inoperable or Persistent/Recurrent After Surgical and/or Interventional Treatment Chronic Thromboembolic Pulmonary Hypertension
Principal Investigator 
Nathan Brunner

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT03689244
Status 
Recruiting
Study Start/End 
Jul 16, 2020 to Apr 1, 2022
Name/Title 
Mami Okada, Research Coordinator
Phone 
604-875-4111 ext.69831
Email Address 
mami.okada@vch.ca
Purpose of Study 

The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.